Nextstellis Kit
Product Images NDC 51862-258

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Nextstellis (NDC 51862-258). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mayne Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Nextstellis 01)

The text provides a chart that shows the number of women who develop blood clots out of 10,000 women years based on various factors such as whether they are pregnant or postpartum, and whether they are a COC (combination oral contraceptive) user or not. The chart does not provide any information about the causes, symptoms, or treatments for blood clots.*

FDA Label Image

Chemical Structure (Nextstellis 02)

This text provides information regarding studies comparing the effects of ever using combined oral contraceptives (COC) versus never using them, as well as studies comparing current COC use versus never use. The studies are identified by name, date, and author, and the results of each study are presented in terms of effect estimates (odds ratios or relative risks) with corresponding confidence intervals. However, no further details or conclusions are provided, so it is unclear what the overall findings or implications of these studies may be.*

FDA Label Image

Chemical Structure (Nextstellis 03)

FDA Label Image

Figure (Nextstellis 04)

FDA Label Image

Figure (Nextstellis 05)

This text provides information on different methods of birth control and their effectiveness rates in terms of pregnancies per 100 women in one year. It lists various options like implants, intrauterine devices (IUDs), birth control pills, condoms, and others. The text emphasizes that there is no 100% effective method, and even popular options like birth control pills or condoms can fail. The text also suggests that certain practices, like avoiding sex during the most fertile days of the menstrual cycle or using withdrawal and spermicide, are not reliable methods of birth control.*

FDA Label Image

Principal Display Panel (Kit Carton)

This appears to be a set of instructions related to a medication called Nextstellis, which is made up of drospirenone and estetrol tablets. The text mentions a day label strip that begins with the first day of the patient's period, and instructs the patient to take the pills in the direction shown by arrows. No further information is available.*

FDA Label Image

Nextstellis 07

This is a description of a package of combined oral contraceptive pills. It contains 26 tablets, 24 active tablets, and 4 inert tablets. The active tablets contain 3 mg drospirenone and 142 mg esterol. The recommended dosages can be found in the prescribing information. The package is designed to prevent pregnancy and does not protect against sexually transmitted diseases or HIV infection. The pills should be stored at controlled room temperature of 20°C to 25°C. It comes with a patient information leaflet and is child resistant. Mayne Pharma distributes this product of Germany.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.